Results 211 to 220 of about 69,829 (275)

Retreatment of patients with chronic hepatitis C, subtype 3a, and cirrhosis, who previously failed a regimen containing second-generation NS5A inhibitors with sofosbuvir + glecaprevir/pibrentasvir and ribavirin for 16-24 weeks. [PDF]

J Virol
Fedorchenko SV, Klimenko Z, Martynovich T, Solianyk I, Suprunenko T.   +4 more
europepmc   +1 more source

Outcomes of Direct-Acting Antivirals Versus Interferon-Based Therapy in Chronic Hepatitis C Infection.

Cureus
Chowdhury R, Rashid W, Singh T, Rehman A, Daterdiwala NF, Mkosi V, Limbu B, Bukhari SA, Ramadhan A, Dabas MM, Shehryar A, Khan R.   +11 more
europepmc   +1 more source

Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID‐19

Journal of Medical Virology, 2020
Confronting the challenge of the outbreak of COVID‐19 should sharpen our focus on global drug access as a key issue in antiviral therapy testing. The testing and adoption of effective therapies for novel coronaviruses are hampered by the challenge of ...
Jahan S Khalili
exaly   +2 more sources

Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

Lancet, The, 2020
Kwok-Cheung Lung, Tom Wai-Hin Chung, Hoi-Ping Shum   +2 more
exaly   +2 more sources

Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection

Gastroenterology, 2017
Paul Y Kwo, Cheng-Yuan Peng, Brian L Pearlman   +2 more
exaly   +2 more sources

Ribavirin: A clinical overview [PDF]

European Journal of Epidemiology, 1986
Ribavirin, a broad spectrum, non-interferon-inducing virustatic chemotherapeutic agent, demonstrates activity against a wide range of RNA and DNA viruses, including the retrovirus known to cause the acquired immune deficiency syndrome. The drug's proposed mechanism of action, as well as pharmacokinetics are discussed, and preclinical toxicity, safety ...
R Smith, G Banks, H Fernandez
openaire   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Ribavirin

Pediatrics, 1987
Immunization has proved to be the most effective way of controlling viral diseases, and the development of antiviral drugs has lagged behind the development of antibacterial agents. Many of the early antiviral agents were DNA nucleoside analogs such as idoxuridine, cytarabine, and vidarabine, which competitively inhibited replication of DNA viruses ...
openaire   +4 more sources

Ribavirin Analogs

Clinics in Liver Disease, 2009
Ribavirin is ineffective against hepatitis C virus as mono-therapy but is critical in attaining both early virologic response and sustained virologic response when combined with pegylated interferon. Ribavirin has significant dose-limiting toxicities, the most important of which is hemolytic anemia.
William W, Shields, Paul J, Pockros
openaire   +2 more sources

Favipiravir and Ribavirin Treatment of Epidemiologically Linked Cases of Lassa Fever

Clinical Infectious Diseases, 2017
Vanessa N Raabe, Aneesh K Mehta, Sharon Vanairsdale   +2 more
exaly   +2 more sources